Biocartis wraps up $100m in Series C financing
This article was originally published in Scrip
Executive Summary
Swiss molecular diagnostics specialist Biocartis has just closed a €71m ($100m) series C funding round, which included existing investor and collaborator Johnson & Johnson. It is one of the largest fundraisings in the life sciences sector this year, which is toppedby the $150 million series C round into medtech drug delivery company Valeritas in September and just behind the $107m raised by heart device firm Cameron Health in May. The round is also the second largest venture financing by a European company this year. The largest European venture financing to date has been the $132 million Series E round into Symphogen in January and just ahead of the £60 million raised by the UK inflammation company Circassia in April.